Wisesat Space (SAIQ) traded up 9.97 % during a 24 hours period ending at 08:07 PM Central Europe on Tuesday 27th. One Wisesat Space stock can currently be bought for about USD 7.39 on popular exchanges. Current supply of Wisesat Space stocks is 17.1 mn. Wisesat Space has a current market capitalization of USD 118.7 mn and approximately USD 59.1 mn worth of Wisesat Space was traded on exchanges in the last 24 hours. Since last month end, Wisesat Space has traded -36.74 % down. Simple moving average of last 200 days is at USD 10.04. The highest price of past 52 weeks was recorded at USD 12.95 on 09/28/2026. 52 weeks low was at USD 1.76 on 10/02/2026.
Summary of the latest news for Wisesat Space
WISeSat.Space Holdings Corp. announced on 26 October 2026 a binding letter of intent with its sister company SEALSQ Corp. The agreement outlines a planned acquisition of satellite capacity and related operational services from WISeSat.Space’s twelve‑satellite constellation, alongside mission‑control, ground‑segment and support services. The transaction is intended to establish the initial orbital and terrestrial infrastructure for the Quantum Spatial Orbital Cloud (QSOC), a platform that will combine satellite connectivity with SEALSQ’s post‑quantum security and identity technologies. WISeSat.Space will continue to procure and operate the satellites, while SEALSQ will develop and commercialise QSOC’s security‑service layer. The deal follows the company’s recent Nasdaq listing and a $10 million private equity investment by SEALSQ, positioning WISeSat.Space to monetize its satellite capacity and expand its secure space‑infrastructure offering.
Here is how related stocks have performed in the past 24 hours:
Journey Medical (DERM) traded down -1 % and now trades at USD 5. Current market capitalisation for Journey Medical is USD 141.7 mn.
Neighborhood Intelligence (NXH) traded down -3.66 % and now trades at USD 1.58. Neighborhood Intelligence has a market capitalisation of USD 142 mn. Neighborhood Intelligence Inc. (NASDAQ: NXH) announced that it will publish its third‑quarter 2026 financial results after market close on November 5, 2026. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the forthcoming results and answer investor queries. Participants can submit questions ahead of the call via email, and a replay of the session will be made available on the company’s Investor Relations website shortly after the live broadcast. Neighborhood Intelligence, formerly Bed Bath & Beyond, continues to focus on its three main business segments—Omni‑Channel Retail, Home Services, and Home Ownership—while maintaining a blockchain asset portfolio. The announcement provides a schedule for stakeholders to follow as the company prepares to disclose its quarterly performance.
Bhav Acquisition (BHAV) traded flat 0 % and now trades at USD 10.1. Bhav Acquisition has a market capitalisation of USD 141.7 mn.
Eagle Nuclear Energy (NUCL) traded down -0.63 % and now trades at USD 4.72. Current market capitalisation for Eagle Nuclear Energy is USD 141.4 mn. Eagle Nuclear Energy Corp. (NASDAQ: NUCL) continues to advance its Aurora Uranium Project toward a Pre‑Feasibility Study, with all major contractors in place and a 27,000‑foot drill program ready to commence pending regulatory approvals in Oregon. The company has engaged new technical and government affairs advisors to support the drilling and resource upgrade efforts. Eagle’s cash position remains robust, with no debt, and the company has been added to a global uranium index, potentially enhancing its exposure to institutional investors. Aurora, which holds a significant equity interest in Eagle, notes that its share price trades at a discount to the underlying value of the holding, reflecting market perceptions of the project’s development stage. Overall, Eagle’s focus remains on progressing the Aurora project toward a second‑half 2027 feasibility milestone while maintaining a stable financial base.
Atrium Therapeutics (RNA) traded down -1.83 % and now trades at USD 8.2. Current market capitalisation for Atrium Therapeutics is USD 140.3 mn. Atrium Therapeutics announced that the first patient has entered its Phase 1/2 Corventis trial for PRKAG2 syndrome, marking a significant step toward a potential disease‑modifying therapy for this rare cardiomyopathy. The study, enrolling approximately 37 participants, will assess safety, tolerability, and preliminary efficacy of ATR 1072, an RNA‑based treatment designed to silence mutant PRKAG2 messenger RNA. The company expects to release early proof‑of‑concept data in the second half of 2027. This development follows Atrium’s broader pipeline, which includes candidates for other genetic heart conditions, and underscores the firm’s focus on precision RNA therapeutics targeting the heart.